Objective:To illuminate the relation of Zinc-α2-glycoprotein(ZAG)and insulin resistance(IR)in patients with newly diagnosed type 2 diabetes(n T2DM)

and to examine the effect of glucagon-like peptide-1(GLP-1) receptor agonist on ZAG and adiponectin(ADI). Methods:Totally 120 subjects with n T2 DM were assigned randomly to receive placebo(normal saline+metformin)or liraglutide

or metformin + liraglutide for 12 weeks. Before and after the treatment

subjects received 75 g OGTT

euglycemic-hyperinsulinemic clamp(EHCs)

and measurement of metabolic index

serum ZAG and ADI concentrations. Results:Circulating ZAG was significantly lower in n T2 DM than in normal individuals(P<0.01). After 12 weeks of liraglutide or metformin + liraglutide

glycosylated hemoglobin(Hb A1c)

fasting blood glucose(FBG)

oral glucose tolerance test 2 hour blood glucose(2h BG)

triglycerides(TG)and HOMA-IR were decreased significantly compared with those of pre- treatment(P < 0. 05)

whereas M values during EHCs were significantly increased(P <0.01). Importantly

after the treatment with liraglutide

circulating ZAG and ADI concentrations were significantly increased along with improved glucose metabolism and insulin sensitivity compared with those of pre-treatment(both P<0.01). Conclusion:Circulating ZAG level

insulin resistance and glucolipid metabolism are significantly increased after with liraglutide treatment. ZAG can be used as a novel biomarker for metabolic syndrome and T2 DM.